🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excellent review of the changes in mHSPC landscape over past decade highlighting the importance of treatment intensification ‼️combining options with different mechanisms of action ✨ progressive improvements in OS with doublets => triplets ✨more adverse events, but manageable

PSCA CAR T-cell therapy for #mCRPC: Phase 1 trial results. Tanya Dorff City of Hope joins Andrea Miyahira Prostate Cancer Foundation to discuss her team's work in Nature Medicine highlighting prostate cancer's immunosuppressive environment > bit.ly/4cOlcSD

Wish you great success in your new role as an ambassador of OncoAlert ♥️ Good job!

🥂🍾 Great news for muscle-invasive bladder cancer patients!!! Durvalumab demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial astrazeneca.com/media-centre/p…

On behalf of International Urology Cancer Summit & the OncoAlert 🚨Network, extending a warm invitation to join us for the second International Urology Cancer Summit #IUCS24 HYBRID & FREE_‼️ September 27, 2024 in Portsmouth UK 🇬🇧 & ONLINE REGISTER urologycancersummit.org/registration/ A great OncoAlert

Positive topline results for darolutamide from Phase III trial in men with metastatic hormone-sensitive prostate cancer (mHSPC) | via ⁦Business Wire⁩ businesswire.com/news/home/2024…

The impact of fibroblast growth factor receptor alterations in clinical outcomes of patients with advanced urothelial carcinoma: Real-world data from #LATAM population out by our OncoAlert 🚨Faculty Dra. María Natalia Gandur Quiroga 🇦🇷and Team This study investigated the prevalence of FGFR

Good point!!!

‼️Lu-PSMA in the neadjuvant setting: could it improve outcomes through direct action on the cells and its potential to induce immune response? No other therapy has been effective for neoadjuvant tretament of PCa so far Ana Paula Garcia Cardoso Daniel Vargas Pivato de Almeida fabio schutz Sandro Cavallero

Excited & honored to be an ASCO #GU25 Featured Voice! Grateful for the opportunity to share insights alongside such esteemed colleagues Michael Serzan, MD Enrique Grande Regina Barragan-Carrillo Dimitra R. Bakaloudi MD, MS, MPA Bárbara Melão, MD, PhD Renee Maria Saliby Emre Yekedüz Looking forward to meaningful discussions!

Now it’s time for the giant Matt Galsky at #GU25 @asco. There’s a clear additive effect of durvalumab over the benefit of neoadjuvant GEMCIS in MIB regardless if pCR was achieved or not. NIAGARA approach is becoming the standard of care….for a while…. Waiting for new ADCs + IO

Extended follow up for Enfortumab/pembro in 1st line advanced UC (m 26mnths). PFS and OS HRs 0.48 & 0.51 respectively. Median duration of response is 2 yrs for the 68% who responded. The 30% with CR have75% & 95% 2 year PFS and OS respectively. Overall G3+ AEs 56 vs 57 % #GU25

Great job!! #GU25

Supports the preferential indication of another non-hormonal therapeutic line for patients who progress despite intensified hormonal blockade, regardless of mHSPC or mCRPC.

We have many unanswered questions in prostate cancer and is crucial to discuss with specialist 🩵

Great talk on how to best combine both biomarker (digital pathology and decipher) and stratify prostate cancer patients

BREAKING from NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection.

Finally had a chance to listen to the discussion EVERYONE in the GU community is talking about via ASCO Virtual Meeting. One of the most thoughtful & eloquent discussions I have ever seen by Jacqueline T. Brown, MD Winship Cancer Institute of Emory University, summarizing excellent presentations from Michiel van der Heijden

Presented at #ASCO25 Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive #ProstateCancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes meetings.asco.org/abstracts-pres… The

#ProstateCancer variants ✨Germline HOXB3 X285K variant: ⏩️risk factor in men of African ancestry ⏩️better response to ARPI Carlos Alberto Toledo Martínez Clovis Fraga T. Pereira OncoAlert Paulo Roberto Salustiano Dr. Rafael Mourato @MSdoNascimento Luis Fernando Sala Ana Paula Garcia Cardoso Daniel Vargas Pivato de Almeida fabio schutz @sandrocavallero